TABLE 3Continued Drug Age Daily dose Maximum dose Comments Rifampicin ⩾15 years 8–12 mg·kg−1 600 mg High-dosage rifampicin therapy is currently evaluated to reduce the duration of anti-TB therapy. 15 years 10–20 mg·kg−1 600 mg Rifapentin ⩾15 years 1200 mg Rifapentin-based regimens can reduce the duration of therapy for TB prevention to 1 month (rifapentin and isoniazid) and active TB to 4 months (rifapentin, isoniazid, moxifloxacin and pyrazinamide (pyrazinamid for 2 months only)). 15 years 1200 mg (12 years of age) Streptomycin ⩾15 years 12–18 mg·kg−1 1000 mg Streptomycin may replace amikacin if amikacin is not available in the treatment of MDR-/RR-TB for patients aged⩾18 years on longer regimens when susceptibility has been demonstrated and adequate measures to monitor for adverse reactions can be ensured. 15 years 20–40 mg·kg−1 1000 mg Terizidon ⩾15 years 10–15 mg·kg−1 1000 mg Terizidone is a condensation product of two cycloserine molecules. Terizidone may be included in the treatment of MDR-/RR-TB patients on longer regimens. 15 years 15–20 mg·kg−1 1000 mg M/W/F: Monday/Wednesday/Friday BPaL: bedaquiline, pretomanid and linezolid BPaLM: bedaquiline, pretomanid, linezolid and moxifloxacin. Dat a from [46] and [58]. https://doi.org/10.1183/2312508X.10024622 125 TREATMENT OF DS-TB AND DR-TB |C. LANGE ET AL.